Due to fedratinib's significant GI side effect profile and the logistical difficulty of measuring thiamine levels, clinicians should proactively provide patients with thiamine supplements, anti-emetics, and anti-diarrheal therapies. Instructing patients to take the drug with food can also help mitigate GI toxicity.

When combining sacituzumab govitecan (SASE) and pembrolizumab (IO), it's crucial to differentiate the cause of diarrhea. SASE-induced diarrhea is similar to standard chemotherapy, while IO-induced diarrhea often presents with bloody stools and severe abdominal cramping.

The clinical definition of constipation is not simply how often you poop, but whether you are adequately emptying your bowels. Having small, partial bowel movements—even multiple times a day—is a form of constipation and is the number one cause of chronic gas and bloating.

To determine if fatigue or cognitive dysfunction is caused by enzalutamide, a clinician suggests a practical approach called the "Stevens Maneuver." The patient stops the drug for two weeks. If symptoms don't improve, the cause is likely something else. If they do improve, the drug is the culprit, and it can often be resumed at a lower dose.

The HORIZON-GEA-01 trial for zanidatumab in gastric cancer mandated prophylactic loperamide (4mg BID) for all patients. This was necessary to manage the high rates of diarrhea (up to 80% of patients), a significant GI toxicity associated with the drug's mechanism of action.

Increasing fiber intake may not improve gut health if an individual's microbiome is already depleted. Research suggests many people in the industrialized world have lost the specific microbes needed to break down diverse fibers. Without these microbes, the fiber passes through without providing benefits, highlighting the need to first restore microbial diversity.

Many common GI diagnoses, like Irritable Bowel Syndrome or gastroparesis, are simply labels for a collection of symptoms defined by criteria, not explanations of the underlying physiological cause. This limits effective, targeted treatment.

The Phase 2 TRAIT study suggests starting adjuvant abemaciclib at a lower dose and escalating over several weeks significantly reduces early discontinuations due to side effects like diarrhea. This strategy helps more patients get through the initial high-toxicity period and remain on the effective dose for the full two-year course.

For patients sensitive to standard loperamide tablets who experience rebound constipation, the liquid formulation offers more flexible, precise dosing. This allows for better symptom control of diarrhea without overcorrecting and causing constipation, improving overall patient tolerance.